97 related articles for article (PubMed ID: 8177909)
1. 3-O-methyldopa attenuates the effects of Madopar on the haloperidol-induced cataleptic behavior and the locomotor activity in the mouse.
Himori N; Tanaka Y; Kurasawa M; Mishima K; Akaike N
Pharmacology; 1994 Apr; 48(4):226-33. PubMed ID: 8177909
[TBL] [Abstract][Full Text] [Related]
2. The COMT inhibitor tolcapone potentiates the anticataleptic effect of Madopar in MPP(+)-lesioned mice.
Himori N; Mishima K
Experientia; 1994 Oct; 50(10):939-42. PubMed ID: 7957769
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
[TBL] [Abstract][Full Text] [Related]
4. Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers.
Crevoisier C; Monreal A; Metzger B; Nilsen T
Eur Neurol; 2003; 49(1):39-44. PubMed ID: 12464717
[TBL] [Abstract][Full Text] [Related]
5. Effects of L-dopa and bromocriptine on haloperidol-induced motor deficits in mice.
Kobayashi T; Araki T; Itoyama Y; Takeshita M; Ohta T; Oshima Y
Life Sci; 1997; 61(26):2529-38. PubMed ID: 9416775
[TBL] [Abstract][Full Text] [Related]
6. Central effects of CGP 37849 and CGP 39551, competitive NMDA receptor antagonists, in mice.
Maj J; Rogóz Z; Skuza G
Pol J Pharmacol; 1993; 45(4):349-60. PubMed ID: 7906989
[TBL] [Abstract][Full Text] [Related]
7. [Behavior disorder in rats induced by Madopar and its pharmacological correction].
Bondarenko NA; Bondarenko NA
Farmakol Toksikol; 1985; 48(4):31-4. PubMed ID: 2864283
[TBL] [Abstract][Full Text] [Related]
8. Ketotifen can antagonise changes in sensitivity of cerebral dopamine receptors: behavioural correlates in rodent and primate.
Barnes JC; Barnes NJ; Barnes NM; Costall B; Domeney AM; Naylor RJ
Neuropharmacology; 1987 Jul; 26(7A):693-700. PubMed ID: 3114665
[TBL] [Abstract][Full Text] [Related]
9. KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity.
Kanda T; Shiozaki S; Shimada J; Suzuki F; Nakamura J
Eur J Pharmacol; 1994 May; 256(3):263-8. PubMed ID: 8045270
[TBL] [Abstract][Full Text] [Related]
10. Nicotine potentiates haloperidol-induced catalepsy and locomotor hypoactivity.
Emerich DF; Zanol MD; Norman AB; McConville BJ; Sanberg PR
Pharmacol Biochem Behav; 1991 Apr; 38(4):875-80. PubMed ID: 1871200
[TBL] [Abstract][Full Text] [Related]
11. Central effects of SL 82.0715, an antagonist of polyamine site of the NMDA receptor complex.
Dereń-Wesołek A; Maj J
Pol J Pharmacol; 1993; 45(5-6):467-80. PubMed ID: 7912135
[TBL] [Abstract][Full Text] [Related]
12. 3-O-methyldopa and the response to levodopa in Parkinson's disease.
Nutt JG; Woodward WR; Gancher ST; Merrick D
Ann Neurol; 1987 Jun; 21(6):584-8. PubMed ID: 3606046
[TBL] [Abstract][Full Text] [Related]
13. Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.
Marion MH; Stocchi F; Malcolm SL; Quinn NP; Jenner P; Marsden CD
Eur Neurol; 1987; 27 Suppl 1():54-8. PubMed ID: 3322837
[TBL] [Abstract][Full Text] [Related]
14. Coadministration of β-asarone and levodopa increases dopamine in rat brain by accelerating transformation of levodopa: a different mechanism from Madopar.
Huang L; Deng M; Zhang S; Fang Y; Li L
Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):685-90. PubMed ID: 24910244
[TBL] [Abstract][Full Text] [Related]
15. Antipsychotic-like profile of thioperamide, a selective H3-receptor antagonist in mice.
Akhtar M; Uma Devi P; Ali A; Pillai KK; Vohora D
Fundam Clin Pharmacol; 2006 Aug; 20(4):373-8. PubMed ID: 16867021
[TBL] [Abstract][Full Text] [Related]
16. Blockade of neurotensin receptors affects differently hypo-locomotion and catalepsy induced by haloperidol in mice.
Casti P; Marchese G; Casu G; Ruiu S; Pani L
Neuropharmacology; 2004 Jul; 47(1):128-35. PubMed ID: 15165840
[TBL] [Abstract][Full Text] [Related]
17. Tea component, epigallocatechin gallate, potentiates anticataleptic and locomotor-sensitizing effects of caffeine in mice.
Kasture SB; Gaikar M; Kasture V; Arote S; Salve B; Rosas M; Cotti E; Acquas E
Behav Pharmacol; 2015 Feb; 26(1-2):125-32. PubMed ID: 25144514
[TBL] [Abstract][Full Text] [Related]
18. Estrogen and haloperidol-induced versus handling-related catalepsy in male rats.
De Ryck M; Hruska RE; Silbergeld EK
Pharmacol Biochem Behav; 1982 Nov; 17(5):1027-35. PubMed ID: 7178196
[TBL] [Abstract][Full Text] [Related]
19. Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers.
Crevoisier C; Hoevels B; Zürcher G; Da Prada M
Eur Neurol; 1987; 27 Suppl 1():36-46. PubMed ID: 3428308
[TBL] [Abstract][Full Text] [Related]
20. Comparative multiple-dose pharmacokinetics of controlled-release levodopa products.
Grahnén A; Eckernäs SA; Collin C; Ling-Andersson A; Tiger G; Nilsson M
Eur Neurol; 1992; 32(6):343-8. PubMed ID: 1490503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
